单侧MRI可疑灶男性在接受靶向活检时对侧系统活检的临床价值
前瞻性研究纳入655例单侧MRI可疑灶、于门诊接受MRI引导经会阴靶向活检的男性,所有患者均行靶向活检加对侧系统活检。对侧系统活检仅使7/655(1%)检出靶向活检漏诊的临床显著前列腺癌(csPCa),均为低体积Gleason GG2、适合主动监测者;对侧活检信息未影响全腺体治疗分配及术中神经保留。
要点
- 单侧MRI可疑灶男性中,对侧系统活检额外检出csPCa仅7/655(1%),均为低体积Gleason GG2。
- 对侧活检未影响全腺体治疗分配和术中神经保留。
- 对侧活检可能有助于确定前列腺癌多灶性,以评估局灶治疗资格。
核心结论
- 在单侧MRI可疑灶、接受MRI引导经会阴靶向活检的男性中,对侧系统活检对csPCa检出和全腺体治疗风险评估价值有限,但可能对确定前列腺癌多灶性(考虑局灶治疗资格)有重要意义。
研究设计与样本
- 前瞻性研究,纳入2022年5月至2023年12月间655例连续的单侧MRI可疑灶、于门诊接受MRI引导经会阴融合活检的男性。
- 所有患者活检前均行MRI,随后行MRI引导经会阴融合活检,每个病灶至少4条靶向穿刺加5条对侧系统穿刺。
主要发现
- 任何前列腺癌和csPCa(Gleason分级分组GG≥2)分别检出564/655(85%)和471/655(71%),中位年龄66岁、PSA 7.6 ng/mL。
- 对侧系统活检检出、而MRI靶向活检漏诊的csPCa为7/655(1%),均为低体积Gleason GG2、适合主动监测。
- 在MRI靶向活检检出csPCa的464例中,70/464(15%)的对侧活检检出匹配的Gleason GG2-5前列腺癌,另7例对侧活检Gleason GG更高。
- 对侧活检的额外信息似乎未影响全腺体治疗分配和术中神经保留。
临床怎么用
- 原文结论指出,对侧系统活检对csPCa检出和全腺体治疗风险评估价值有限,但可能对确定前列腺癌多灶性(考虑局灶治疗资格)有重要意义。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the additional prostate cancer detection yield and clinical implications of performing contralateral systematic biopsies in men with unilateral suspicious magnetic resonance imaging (MRI) findings undergoing MRI-guided transperineal (TP) biopsies in an outpatient clinic. PATIENTS AND METHODS: A prospective study of 655 consecutive men with unilateral MRI suspicious findings undergoing office-based MRI-guided TP biopsies between May 2022 and December 2023. All men had pre-biopsy MRI followed by MRI-guided TP fusion biopsies with at least four targeted cores per lesion plus five contralateral systematic biopsies. The primary objective was the clinically significant prostate cancer (csPCa) detection rate of contralateral systematic biopsies in men with no or insignificant PCa on targeted biopsies. Secondary objectives included the impact of contralateral biopsies on PCa grade upgrading, additional insignificant PCa diagnoses, and the clinical implications of multifocal csPCa detected on both targeted and contralateral cores. RESULTS: Any and csPCa (Gleason Grade Group [GG] ≥2) was detected in 564/655 (85%) and 471/655 (71%) men with a median age of 66 years and PSA level of 7.6 ng/mL. Overall, seven of 655 (1%) men had csPCa detected by contralateral systematic biopsies missed on MRI-targeted biopsy, all of whom had low-volume Gleason GG 2 PCa eligible for active surveillance. Furthermore, 70/464 (15%) men with csPCa on MRI-targeted biopsy had matching Gleason GG 2-5 PCa on contralateral biopsy, and another seven had higher Gleason GG. However, the additional information from contralateral biopsies did not seem to influence whole-gland treatment allocation and nerve-sparing during surgery. CONCLUSION: Contralateral systematic biopsies in men with unilateral MRI findings undergoing MRI-guided TP targeted biopsies have limited value for csPCa detection and risk assessment for whole-gland treatment but may be important for determining PCa multifocality considering focal therapy eligibility.
引用
- Boesen L, Nørgaard N, Bisbjerg R, et al. Clinical value of contralateral biopsies in men with unilateral MRI foci undergoing targeted biopsy. BJU Int. 2024. PMID: 39530406. doi:10.1111/bju.16579
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。